JP2013500015A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013500015A5 JP2013500015A5 JP2012521778A JP2012521778A JP2013500015A5 JP 2013500015 A5 JP2013500015 A5 JP 2013500015A5 JP 2012521778 A JP2012521778 A JP 2012521778A JP 2012521778 A JP2012521778 A JP 2012521778A JP 2013500015 A5 JP2013500015 A5 JP 2013500015A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- lentiviral vector
- seq
- virus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 claims description 54
- 239000002245 particle Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 37
- 102000036639 antigens Human genes 0.000 claims description 37
- 108091007433 antigens Proteins 0.000 claims description 37
- 108020004707 nucleic acids Proteins 0.000 claims description 22
- 102000039446 nucleic acids Human genes 0.000 claims description 22
- 150000007523 nucleic acids Chemical class 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 15
- 238000004806 packaging method and process Methods 0.000 claims description 15
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 14
- 235000013922 glutamic acid Nutrition 0.000 claims description 14
- 239000004220 glutamic acid Substances 0.000 claims description 14
- 108090000288 Glycoproteins Proteins 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 101500008206 Sindbis virus Spike glycoprotein E2 Proteins 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 8
- 210000004443 dendritic cell Anatomy 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 108010089520 pol Gene Products Proteins 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 5
- 108010061833 Integrases Proteins 0.000 claims description 5
- 238000006467 substitution reaction Methods 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 241000710960 Sindbis virus Species 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 229940021993 prophylactic vaccine Drugs 0.000 claims description 4
- 101710177291 Gag polyprotein Proteins 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- 101710125418 Major capsid protein Proteins 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 108020001507 fusion proteins Proteins 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 claims description 3
- 229960000310 isoleucine Drugs 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 239000004474 valine Substances 0.000 claims description 3
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 230000037430 deletion Effects 0.000 claims description 2
- 238000012217 deletion Methods 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102220036548 rs140382474 Human genes 0.000 claims description 2
- -1 RAGE Proteins 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229940021747 therapeutic vaccine Drugs 0.000 claims 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 102000003425 Tyrosinase Human genes 0.000 claims 2
- 108060008724 Tyrosinase Proteins 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000004041 dendritic cell maturation Effects 0.000 claims 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims 1
- 108700012439 CA9 Proteins 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 1
- 108010033547 Carbonic Anhydrase I Proteins 0.000 claims 1
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 claims 1
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 208000000655 Distemper Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 241000709661 Enterovirus Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 claims 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 claims 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 1
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 claims 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 claims 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims 1
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108010010995 MART-1 Antigen Proteins 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims 1
- 108010057466 NF-kappa B Proteins 0.000 claims 1
- 102000003945 NF-kappa B Human genes 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims 1
- 241000710778 Pestivirus Species 0.000 claims 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 1
- 241000709664 Picornaviridae Species 0.000 claims 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 241000702263 Reovirus sp. Species 0.000 claims 1
- 241000702670 Rotavirus Species 0.000 claims 1
- 241000714474 Rous sarcoma virus Species 0.000 claims 1
- 108700026226 TATA Box Proteins 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 108090000333 Transgelin Proteins 0.000 claims 1
- 102000003932 Transgelin Human genes 0.000 claims 1
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 108090000848 Ubiquitin Proteins 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 108090000237 interleukin-24 Proteins 0.000 claims 1
- 102000003898 interleukin-24 Human genes 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012737 microarray-based gene expression Methods 0.000 claims 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 108010076039 Polyproteins Proteins 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22849109P | 2009-07-24 | 2009-07-24 | |
| US61/228,491 | 2009-07-24 | ||
| PCT/US2010/042870 WO2011011584A1 (en) | 2009-07-24 | 2010-07-22 | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015008415A Division JP6170952B2 (ja) | 2009-07-24 | 2015-01-20 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013500015A JP2013500015A (ja) | 2013-01-07 |
| JP2013500015A5 true JP2013500015A5 (https=) | 2013-09-05 |
Family
ID=42727669
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012521778A Withdrawn JP2013500015A (ja) | 2009-07-24 | 2010-07-22 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
| JP2015008415A Expired - Fee Related JP6170952B2 (ja) | 2009-07-24 | 2015-01-20 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
| JP2017005594A Withdrawn JP2017060535A (ja) | 2009-07-24 | 2017-01-17 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
| JP2018153946A Expired - Fee Related JP6701280B2 (ja) | 2009-07-24 | 2018-08-20 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015008415A Expired - Fee Related JP6170952B2 (ja) | 2009-07-24 | 2015-01-20 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
| JP2017005594A Withdrawn JP2017060535A (ja) | 2009-07-24 | 2017-01-17 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
| JP2018153946A Expired - Fee Related JP6701280B2 (ja) | 2009-07-24 | 2018-08-20 | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US20110064763A1 (https=) |
| EP (2) | EP2770061B1 (https=) |
| JP (4) | JP2013500015A (https=) |
| KR (1) | KR101790187B1 (https=) |
| CN (1) | CN102482329B (https=) |
| AU (1) | AU2010276194B2 (https=) |
| BR (1) | BR112012001653A2 (https=) |
| CA (1) | CA2768938C (https=) |
| CY (1) | CY1121159T1 (https=) |
| DK (2) | DK2770061T3 (https=) |
| EA (1) | EA032403B1 (https=) |
| ES (2) | ES2702274T3 (https=) |
| HR (2) | HRP20140327T4 (https=) |
| HU (1) | HUE043032T2 (https=) |
| IL (1) | IL217679A (https=) |
| LT (1) | LT2770061T (https=) |
| ME (1) | ME01720B (https=) |
| MX (1) | MX2012001075A (https=) |
| NZ (1) | NZ597804A (https=) |
| PL (2) | PL2770061T3 (https=) |
| PT (2) | PT2770061T (https=) |
| RS (2) | RS53257B2 (https=) |
| SG (1) | SG177744A1 (https=) |
| SI (2) | SI2456786T2 (https=) |
| SM (2) | SMT201800656T1 (https=) |
| TR (1) | TR201819229T4 (https=) |
| WO (1) | WO2011011584A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2657737T3 (es) * | 2009-07-15 | 2018-03-06 | Calimmune Inc. | Vector dual para la inhibición del virus de la inmunodeficiencia humana |
| WO2012112691A1 (en) * | 2011-02-15 | 2012-08-23 | Immune Design Corp. | Methods for enhancing immunogen specific immune responses by vectored vaccines |
| EA027236B1 (ru) | 2011-04-08 | 2017-07-31 | Иммьюн Дизайн Корп. | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа |
| WO2013116656A1 (en) * | 2012-02-03 | 2013-08-08 | Emory University | Immunostimulatory compositions, particles, and uses related thereto |
| EP2844746A4 (en) | 2012-03-26 | 2016-07-20 | Univ California | PSEUDOTYPIZED LENTIVIRES WITH NIPAH VIRUS COVERS AND METHOD OF USE THEREOF |
| US9713635B2 (en) * | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| WO2013149167A1 (en) * | 2012-03-30 | 2013-10-03 | Immune Design Corp. | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
| US8323662B1 (en) * | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| HRP20181102T1 (hr) | 2012-05-16 | 2018-09-07 | Immune Design Corp | Cjepiva za hsv-2 |
| EP2943203A4 (en) * | 2013-01-11 | 2016-08-24 | Scripps Research Inst | METHOD AND COMPOSITIONS FOR INCREASING THE TRANSDUCTION EFFICIENCY OF RETROVIRAL VECTORS |
| GB201308772D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations Ltd | Vectors |
| SMT202000531T1 (it) | 2014-03-09 | 2020-11-10 | Univ Pennsylvania | Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc) |
| KR20170032373A (ko) | 2014-07-15 | 2017-03-22 | 이뮨 디자인 코포레이션 | Tlr4 작용제 보조제 및 렌티바이러스 벡터를 이용한 프라임-부스트 요법 |
| WO2016118715A1 (en) * | 2015-01-21 | 2016-07-28 | Cornell University | Viral vectors for prophylaxis and therapy of hemoglobinopathies |
| US20180112180A1 (en) * | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| CN114262380A (zh) | 2015-03-18 | 2022-04-01 | 欧姆尼赛特有限公司 | 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法 |
| DK3283658T3 (da) | 2015-05-18 | 2020-05-18 | Calimmune Inc | Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer |
| US20190119350A1 (en) | 2015-09-09 | 2019-04-25 | Immune Design Corp. | Ny-eso-1 specific tcrs and methods of use thereof |
| WO2017083291A1 (en) * | 2015-11-09 | 2017-05-18 | Immune Design Corp. | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| AU2016354102B2 (en) | 2015-11-09 | 2022-05-12 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids |
| JP2019509275A (ja) * | 2016-02-23 | 2019-04-04 | イミューン デザイン コーポレイション | マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム |
| WO2017152042A2 (en) * | 2016-03-04 | 2017-09-08 | New York University | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity |
| MX2018012472A (es) | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2017181152A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Cd80 variant immunomodulatory proteins and uses thereof |
| EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| EP3235828A1 (en) * | 2016-04-21 | 2017-10-25 | Genethon | Stable pseudotyped lentiviral particles and uses thereof |
| WO2018022946A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| WO2018075978A1 (en) | 2016-10-20 | 2018-04-26 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
| SG11201907769XA (en) | 2017-03-16 | 2019-09-27 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| KR20190141146A (ko) | 2017-03-16 | 2019-12-23 | 알파인 이뮨 사이언시즈, 인코포레이티드 | Pd-l2 변이체 면역조절 단백질 및 그의 용도 |
| EP3596116B1 (en) | 2017-03-16 | 2023-09-06 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| CA3062426A1 (en) | 2017-05-08 | 2018-11-15 | Flagship Pioneering Innovations V, Inc. | Compositions for facilitating membrane fusion and uses thereof |
| BR112020007542A2 (pt) | 2017-10-18 | 2020-12-01 | Alpine Immune Sciences, Inc. | proteínas imunomoduladoras ligantes de icos variantes e composições e métodos relacionados |
| AU2019205273B2 (en) | 2018-01-03 | 2024-04-04 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| US11116833B2 (en) * | 2018-02-08 | 2021-09-14 | George Mason University | Method and system for inactivating virus infectivity for producing live-attenuated vaccines |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN112955174A (zh) | 2018-07-09 | 2021-06-11 | 旗舰先锋创新V股份有限公司 | 融合剂脂质体组合物和其用途 |
| US12241079B2 (en) | 2018-09-14 | 2025-03-04 | The Children's Hospital Of Philadelphia | Compositions and methods for hemoglobin production |
| CN113631718A (zh) | 2018-11-14 | 2021-11-09 | 旗舰先锋创新V股份有限公司 | 用于特定隔室货物递送的组合物和方法 |
| JP7520008B2 (ja) * | 2018-11-23 | 2024-07-22 | ビラ セラピューティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｖｓｖキメラベクター |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| US20220364119A1 (en) | 2019-06-14 | 2022-11-17 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst | Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle |
| WO2021022308A2 (en) * | 2019-08-01 | 2021-02-04 | The Regents Of The University Of California | Non-viral transgenesis |
| CN110982842B (zh) * | 2019-12-31 | 2023-04-18 | 山西大学 | 一种慢病毒表达载体的设计及应用 |
| CA3185952A1 (en) * | 2020-07-15 | 2022-01-20 | Pierre Charneau | Sars-cov-2 immunogenic compositions, vaccines, and methods |
| KR20240028975A (ko) | 2021-04-08 | 2024-03-05 | 사나 바이오테크놀로지, 인크. | Cd8-특이적 항체 구조체들 및 이의 조성물 |
| KR20240099340A (ko) * | 2021-10-25 | 2024-06-28 | 젠비보, 인크. | 치료제 또는 백신 전달을 위한 조성물 및 방법 |
| US20230340627A1 (en) * | 2022-04-05 | 2023-10-26 | Bio-Rad Laboratories, Inc. | Analysis of viral particles by digital assay |
| US20250302998A1 (en) | 2022-05-09 | 2025-10-02 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
| EP4536836A1 (en) | 2022-06-07 | 2025-04-16 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| WO2025106748A1 (en) * | 2023-11-15 | 2025-05-22 | Genvivo, Inc. | Compositions and methods for therapeutic delivery |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4569794A (en) | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| ATE112314T1 (de) | 1988-05-17 | 1994-10-15 | Lubrizol Genetics Inc | Pflanzliches ubiquitinpromotorsystem. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| CA2017507C (en) | 1989-05-25 | 1996-11-12 | Gary Van Nest | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| TW279133B (https=) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| DE69333115D1 (de) | 1992-09-22 | 2003-08-28 | Biofocus Discovery Ltd | Rekombinante viren, die an ihrer äusseren oberfläche ein nichtvirales polypeptid präsentieren |
| US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| US5279552A (en) | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
| US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5660835A (en) | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
| CA2224907A1 (en) | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| FR2747046B1 (fr) | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
| WO1998032869A1 (en) | 1997-01-29 | 1998-07-30 | Neurosearch A/S | Expression vectors and methods for in vivo expression of therapeutic polypeptides |
| US6432699B1 (en) * | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
| US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| ZA988446B (en) | 1997-09-18 | 2000-03-22 | Res Dev Foundation | Production of vaccines using arthropod vectored viruses. |
| WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| DE69941049D1 (de) * | 1998-05-22 | 2009-08-13 | Oxford Biomedica Ltd | Retrovirales verabreichungssystem |
| WO2000055378A1 (en) * | 1999-03-16 | 2000-09-21 | Dana-Farber Cancer Institute, Inc. | Lentiviral vector system for high quantity screening |
| DE60044125D1 (de) | 1999-04-14 | 2010-05-20 | Novartis Vaccines & Diagnostic | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| CA2392010A1 (en) | 1999-08-27 | 2001-03-08 | Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| PT1221968E (pt) | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
| US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
| US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
| US7241275B2 (en) | 1999-10-14 | 2007-07-10 | Becton, Dickinson And Company | Intradermal needle |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
| US6627442B1 (en) * | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| EP1368058A4 (en) * | 2001-03-02 | 2005-01-12 | Merck & Co Inc | VIRAL REPORTER PARTICLES |
| WO2002101057A1 (fr) * | 2001-06-08 | 2002-12-19 | Dnavec Research Inc. | Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur |
| JP4344858B2 (ja) | 2001-09-13 | 2009-10-14 | カリフォルニア インスティチュート オブ テクノロジー | 細胞内で抗ウイルス性小ｒｎａ分子を発現させる方法 |
| EP1451316B1 (en) | 2001-09-13 | 2014-08-06 | California Institute Of Technology | Method for producing transgenic birds |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| US7195916B2 (en) | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| US6971999B2 (en) | 2001-11-14 | 2005-12-06 | Medical Instill Technologies, Inc. | Intradermal delivery device and method |
| BRPI0307434B8 (pt) | 2002-02-04 | 2021-06-22 | Becton Dickinson Co | dispositivo para aplicar ou retirar uma substância através da pele. |
| US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
| US7047070B2 (en) | 2002-04-02 | 2006-05-16 | Becton, Dickinson And Company | Valved intradermal delivery device and method of intradermally delivering a substance to a patient |
| US6780171B2 (en) | 2002-04-02 | 2004-08-24 | Becton, Dickinson And Company | Intradermal delivery device |
| JP4343708B2 (ja) * | 2002-04-26 | 2009-10-14 | アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． | 改良型キメラ糖タンパク質と、類型化されたレンチウイルス |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| EP1535627B1 (en) | 2002-08-16 | 2008-07-09 | Japan Science and Technology Agency | Recombinant bcg vaccine |
| AU2003297474A1 (en) | 2002-12-18 | 2004-07-14 | Salk Institute For Biological Studies | Methods of inhibiting gene expression by rna interference |
| US7090837B2 (en) | 2003-01-21 | 2006-08-15 | The Salk Institute For Biological Studies | Compositions and methods for tissue specific targeting of lentivirus vectors |
| US20050112139A1 (en) | 2003-10-23 | 2005-05-26 | Nmk Research, Llc | Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| US7108679B2 (en) | 2004-03-11 | 2006-09-19 | Becton, Dickinson And Company | Intradermal syringe and needle assembly |
| WO2005113584A1 (en) * | 2004-04-29 | 2005-12-01 | Board Of Regents, University Of Texas System | Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting |
| US20080227736A1 (en) | 2004-06-03 | 2008-09-18 | Regents Of The University Of California, | Targeting Pseudotyped Retroviral Vectors |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2006031996A2 (en) * | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
| RU2007134371A (ru) * | 2005-02-16 | 2009-03-27 | Лентиджен Корпорейшн (Us) | Лентивирусные векторы и их применение |
| EP1885186B1 (en) | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| US8329162B2 (en) * | 2006-07-21 | 2012-12-11 | California Institute Of Technology | Targeted gene delivery for dendritic cell vaccination |
| PL2068918T5 (pl) | 2006-09-26 | 2024-12-02 | Access To Advanced Health Institute | Kompozycja szczepionki zawierająca syntetyczny adiuwant |
| WO2009035528A2 (en) | 2007-09-07 | 2009-03-19 | University Of Georgia Research Foundation, Inc. | Synthetic lipid a derivative |
| PL2222861T3 (pl) | 2007-12-11 | 2018-04-30 | The University Of North Carolina At Chapel Hill | Wektory retrowirusowe ze zmodyfikowanym odcinkiem polipurynowym |
-
2010
- 2010-07-22 RS RS20140158A patent/RS53257B2/sr unknown
- 2010-07-22 SM SM20180656T patent/SMT201800656T1/it unknown
- 2010-07-22 KR KR1020127004625A patent/KR101790187B1/ko not_active Expired - Fee Related
- 2010-07-22 HR HRP20140327TT patent/HRP20140327T4/hr unknown
- 2010-07-22 WO PCT/US2010/042870 patent/WO2011011584A1/en not_active Ceased
- 2010-07-22 TR TR2018/19229T patent/TR201819229T4/tr unknown
- 2010-07-22 MX MX2012001075A patent/MX2012001075A/es active IP Right Grant
- 2010-07-22 NZ NZ597804A patent/NZ597804A/xx not_active IP Right Cessation
- 2010-07-22 ES ES13194273T patent/ES2702274T3/es active Active
- 2010-07-22 LT LTEP13194273.2T patent/LT2770061T/lt unknown
- 2010-07-22 EP EP13194273.2A patent/EP2770061B1/en active Active
- 2010-07-22 EP EP10737715.2A patent/EP2456786B2/en active Active
- 2010-07-22 PT PT13194273T patent/PT2770061T/pt unknown
- 2010-07-22 CA CA2768938A patent/CA2768938C/en active Active
- 2010-07-22 HU HUE13194273A patent/HUE043032T2/hu unknown
- 2010-07-22 ME MEP-2014-29A patent/ME01720B/me unknown
- 2010-07-22 CN CN201080040409.6A patent/CN102482329B/zh not_active Expired - Fee Related
- 2010-07-22 SG SG2012005146A patent/SG177744A1/en unknown
- 2010-07-22 ES ES10737715.2T patent/ES2455544T5/es active Active
- 2010-07-22 DK DK13194273.2T patent/DK2770061T3/en active
- 2010-07-22 RS RS20181505A patent/RS58042B1/sr unknown
- 2010-07-22 AU AU2010276194A patent/AU2010276194B2/en not_active Ceased
- 2010-07-22 SI SI201030576T patent/SI2456786T2/sl unknown
- 2010-07-22 EA EA201270191A patent/EA032403B1/ru not_active IP Right Cessation
- 2010-07-22 PT PT107377152T patent/PT2456786E/pt unknown
- 2010-07-22 JP JP2012521778A patent/JP2013500015A/ja not_active Withdrawn
- 2010-07-22 BR BR112012001653A patent/BR112012001653A2/pt not_active IP Right Cessation
- 2010-07-22 PL PL13194273T patent/PL2770061T3/pl unknown
- 2010-07-22 PL PL10737715T patent/PL2456786T5/pl unknown
- 2010-07-22 SI SI201031821T patent/SI2770061T1/sl unknown
- 2010-07-22 DK DK10737715.2T patent/DK2456786T4/en active
- 2010-07-23 US US12/842,609 patent/US20110064763A1/en not_active Abandoned
-
2011
- 2011-10-20 US US13/277,900 patent/US8187872B2/en active Active
-
2012
- 2012-01-22 IL IL217679A patent/IL217679A/en active IP Right Grant
-
2014
- 2014-04-02 SM SM201400041T patent/SMT201400041B/xx unknown
-
2015
- 2015-01-20 JP JP2015008415A patent/JP6170952B2/ja not_active Expired - Fee Related
- 2015-10-01 US US14/872,633 patent/US20160076055A1/en not_active Abandoned
-
2017
- 2017-01-17 JP JP2017005594A patent/JP2017060535A/ja not_active Withdrawn
-
2018
- 2018-08-20 JP JP2018153946A patent/JP6701280B2/ja not_active Expired - Fee Related
- 2018-11-27 HR HRP20181996TT patent/HRP20181996T1/hr unknown
- 2018-12-27 CY CY20181101398T patent/CY1121159T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013500015A5 (https=) | ||
| JP6170952B2 (ja) | シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター | |
| US8389275B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| JP2015512263A5 (https=) | ||
| JPWO2012053646A1 (ja) | ワクシニアウイルスベクターおよびセンダイウイルスベクターからなるプライム／ブーストワクチン用ウイルスベクター | |
| JP4989224B2 (ja) | Ｄｎａワクチン組成物およびその使用方法 | |
| US20240335531A1 (en) | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection | |
| Wahren et al. | Therapeutic vaccination against HIV | |
| US20130302368A1 (en) | Advanced Prime and Boost Vaccine | |
| WO2022191801A2 (en) | Integrase defective hiv-based lentivirus mediated new generation covid-19 vaccine encoding sars-cov-2 spike protein | |
| CN109923212B (zh) | 用于表达乙肝病毒（hbv）抗原的慢病毒载体 | |
| CN115843270A (zh) | 包括缺失可变结构域的e2多肽的丙型肝炎核酸疫苗 | |
| EP4465999A2 (en) | Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications | |
| Bellier et al. | 26 Retrovirus-Derived Virus-Like Particles | |
| HK40007688A (en) | Lentiviral vectors for expression of hepatitis b virus (hbv) antigens |